Drug Trial Radar · NCT05686239
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
242
Actual
Start
Dec 8, 2022
Primary completion
Apr 9, 2025
Study completion Apr 9, 2025
Sponsor
- Lead sponsor
- Recognify Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with the tasks. Then, subjects will be given either RL-007 or a placebo for 6 weeks and then repeat the cognitive tasks. The researchers will compare the results at the end of the treatment period to the baseline to see if there have been any changes in performance. Additionally, several safety measures will be collected throughout the study (blood pressure, physical exam, ECGs, etc) to evaluate if there are any side effects from taking RL-007.
Conditions
- Cognitive Impairment Associated With Schizophrenia (CIAS)
- Cognitive Impairment
- Schizophrenia
Interventions
RL-007 (Inidascamine)Drug
investigational study drug
PlaceboDrug
placebo capsules matching the appearance and size of the active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- MATRICS Consensus Cognitive Battery (MCCB) neurocognitive compositeTime frame: 6 weeks
Locations
36 sites in 4 countries. Site status is shown where the registry gives one.
Recognify Research Site
Culver City, California
Collaborative Neuroscience Research
Garden Grove, California
Recognify Research Site
Lafayette, California
Recognify Research Site
Oceanside, California
Recognify Research Site
Orange, California
Recognify Research Site
Torrance, California
Recognify Research Site
Hialeah, Florida
Recognify Research Site
Miami, Florida
Recognify Research Site
Miami Lakes, Florida
Recognify Research Site
Atlanta, Georgia
Recognify Research Site
Augusta, Georgia
Recognify Research Site
Gaithersburg, Maryland
Recognify Research Site
Berlin, New Jersey
Recognify Research Site
Brooklyn, New York
Recognify Research Site
Chapel Hill, North Carolina
Recognify Research Site
Cincinnati, Ohio
Recognify Research Site
Cleveland, Ohio
Recognify Research Site
Dallas, Texas
Recognify Research Site
Houston, Texas
Recognify Research Site
Everett, Washington
Recognify Research Site
Burgas, Bulgaria
Recognify Research Site
Kardzhali, Bulgaria
Recognify Research Site
Pleven, Bulgaria
Recognify Research Site
Plovdiv, Bulgaria
Recognify Research Site
Sofia, Bulgaria
Recognify Research Site (a)
Varna, Bulgaria
Recognify Research Site (b)
Varna, Bulgaria
Recognify Research Site
Pilsen, Czechia
Recognify Research Site (a)
Prague, Czechia
Recognify Research Site (b)
Prague, Czechia
Recognify Research Site
Gdansk, Poland
Recognify Research Site
Gorlice, Poland
Recognify Research Site
Kielce, Poland
Recognify Research Site
Lodz, Poland
Recognify Research Site
Lublin, Poland
Recognify Research Site
Poznan, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.